AGIO vs. NVO
Compare and contrast key facts about Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO).
Performance
AGIO vs. NVO - Performance Comparison
Loading graphics...
AGIO vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AGIO Agios Pharmaceuticals, Inc. | 25.61% | -17.16% | 47.55% | -20.69% | -14.57% | -24.14% | -9.26% | 3.56% | -19.35% | 37.00% |
NVO Novo Nordisk A/S | -25.80% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Fundamentals
AGIO:
$1.99B
NVO:
$162.26B
AGIO:
-$7.10
NVO:
$22.15
AGIO:
36.79
NVO:
0.55
AGIO:
1.67
NVO:
0.84
AGIO:
$54.03M
NVO:
$297.20B
AGIO:
$47.68M
NVO:
$240.66B
AGIO:
-$438.48M
NVO:
$153.18B
Returns By Period
In the year-to-date period, AGIO achieves a 25.61% return, which is significantly higher than NVO's -25.80% return. Over the past 10 years, AGIO has underperformed NVO with an annualized return of -2.00%, while NVO has yielded a comparatively higher 5.04% annualized return.
AGIO
- 1D
- 1.06%
- 1M
- 17.09%
- YTD
- 25.61%
- 6M
- -14.67%
- 1Y
- 24.78%
- 3Y*
- 14.18%
- 5Y*
- -8.26%
- 10Y*
- -2.00%
NVO
- 1D
- -0.73%
- 1M
- -0.01%
- YTD
- -25.80%
- 6M
- -36.19%
- 1Y
- -43.88%
- 3Y*
- -20.88%
- 5Y*
- 3.69%
- 10Y*
- 5.04%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AGIO vs. NVO — Risk / Return Rank
AGIO
NVO
AGIO vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AGIO | NVO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.35 | -0.81 | +1.17 |
Sortino ratioReturn per unit of downside risk | 0.93 | -0.99 | +1.93 |
Omega ratioGain probability vs. loss probability | 1.20 | 0.86 | +0.34 |
Calmar ratioReturn relative to maximum drawdown | 0.33 | -0.82 | +1.15 |
Martin ratioReturn relative to average drawdown | 0.70 | -1.41 | +2.12 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| AGIO | NVO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.35 | -0.81 | +1.17 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.14 | 0.10 | -0.24 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.03 | 0.16 | -0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.01 | 0.46 | -0.45 |
Correlation
The correlation between AGIO and NVO is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
AGIO vs. NVO - Dividend Comparison
AGIO has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AGIO Agios Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.94% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Drawdowns
AGIO vs. NVO - Drawdown Comparison
The maximum AGIO drawdown since its inception was -87.36%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AGIO and NVO.
Loading graphics...
Drawdown Indicators
| AGIO | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.36% | -74.70% | -12.66% |
Max Drawdown (1Y)Largest decline over 1 year | -50.89% | -55.03% | +4.14% |
Max Drawdown (5Y)Largest decline over 5 years | -72.16% | -74.70% | +2.54% |
Max Drawdown (10Y)Largest decline over 10 years | -82.86% | -74.70% | -8.16% |
Current DrawdownCurrent decline from peak | -74.68% | -73.49% | -1.19% |
Average DrawdownAverage peak-to-trough decline | -58.57% | -17.56% | -41.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.81% | 31.83% | -8.02% |
Volatility
AGIO vs. NVO - Volatility Comparison
Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 15.62% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| AGIO | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.62% | 9.39% | +6.23% |
Volatility (6M)Calculated over the trailing 6-month period | 79.68% | 38.79% | +40.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 71.01% | 54.16% | +16.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.37% | 37.82% | +19.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 57.30% | 32.28% | +25.02% |
Financials
AGIO vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities